Oramed Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Oramed Pharmaceuticals' es Nadav Kidron , nombrado en Mar 2006, tiene una permanencia de 18.25 años. compensación anual total es $1.66M, compuesta por 27.9% salario y 72.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.87% de las acciones de la empresa, por valor de $2.61M. La antigüedad media del equipo directivo y de la junta directiva es de 11.5 años y 7.8 años, respectivamente.
Información clave
Nadav Kidron
Chief Executive Officer (CEO)
US$1.7m
Compensación total
| Porcentaje del salario del CEO | 27.9% |
| Permanencia del CEO | 18.3yrs |
| Participación del CEO | 2.5% |
| Permanencia media de la dirección | 11.5yrs |
| Promedio de permanencia en la Junta Directiva | 7.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$10m |
| Dec 31 2023 | US$2m | US$463k | US$6m |
| Sep 30 2023 | n/a | n/a | -US$16m |
| Jun 30 2023 | n/a | n/a | -US$20m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$7m | US$491k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | n/a | n/a | -US$35m |
| Nov 30 2021 | n/a | n/a | -US$25m |
| Aug 31 2021 | US$4m | US$466k | -US$22m |
| May 31 2021 | n/a | n/a | -US$18m |
| Feb 28 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Nov 30 2020 | n/a | n/a | -US$15m |
| Aug 31 2020 | US$2m | US$439k | -US$12m |
| May 31 2020 | n/a | n/a | -US$11m |
| Feb 29 2020 | n/a | n/a | -US$13m |
| Nov 30 2019 | n/a | n/a | -US$13m |
| Aug 31 2019 | US$2m | US$419k | -US$14m |
| May 31 2019 | n/a | n/a | -US$15m |
| Feb 28 2019 | n/a | n/a | -US$15m |
| Nov 30 2018 | n/a | n/a | -US$14m |
| Aug 31 2018 | US$2m | US$436k | -US$13m |
| May 31 2018 | n/a | n/a | -US$12m |
| Feb 28 2018 | n/a | n/a | -US$10m |
| Nov 30 2017 | n/a | n/a | -US$10m |
| Aug 31 2017 | US$1m | US$400k | -US$10m |
Compensación vs. Mercado: La compensación total de Nadav($USD1.66M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD673.68K).
Compensación vs. Ingresos: La compensación de Nadav ha sido consistente con los resultados de la empresa en el último año.
CEO
Nadav Kidron (50 yo)
18.3yrs
Permanencia
US$1,659,222
Compensación
Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 18.3yrs | US$1.66m | 2.46% $ 2.7m | |
| Chief Scientific Officer & Director | 18.3yrs | US$1.11m | 0.21% $ 230.9k | |
| CFO, Treasurer & Secretary | no data | US$1.05m | sin datos | |
| Chief Operating & Business Officer | 4.8yrs | US$1.28m | 0.43% $ 463.2k |
11.5yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ORMP es experimentado (11.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 18.3yrs | US$1.66m | 2.46% $ 2.7m | |
| Chief Scientific Officer & Director | 18.3yrs | US$1.11m | 0.21% $ 230.9k | |
| Member of Scientific Advisory Board | 4.4yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 17.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.6yrs | US$20.00k | sin datos | |
| Member of Scientific Advisory Board | 15.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.5yrs | sin datos | sin datos | |
| Independent Director | 16.7yrs | US$112.28k | 0.080% $ 87.2k | |
| Member of the Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2yrs | sin datos | sin datos | |
| Independent Director | 4.5yrs | US$127.28k | 0.075% $ 82.1k | |
| Member of Scientific Advisory Board | 4.4yrs | sin datos | sin datos |
7.8yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de ORMP se considera experimentada (7.8 años de antigüedad promedio).